TVM Capital Healthcare

Helmut Schühsler chairs the firm and serves as CEO, with investment committee authority over all commitments. He co-founded the original TVM Capital Life Science franchise in Munich before establishing the standalone Dubai operation in 2012. The firm maintains a flat partnership structure with sector leads and operating partners feeding into a centralized investment committee.

Sourcing relies on the firm's dual footprint in Europe and the Gulf. European deal flow typically originates from Schühsler's legacy venture network and academic medical centers, while Middle East opportunities are identified through sovereign healthcare procurement pipelines and mandatory insurance rollouts. The firm's cross-border technology-transfer thesis creates a proprietary bridge that generalist PE firms in the region do not replicate.

The firm is a private equity asset manager, not a family office. It raises capital from institutional limited partners, including development finance institutions, sovereign-linked funds, and European pension schemes. There is no single-family wealth backing the platform.

The firm has operated both fund structures and deal-by-deal co-investment vehicles. Following its last traditional fund close in the mid-2010s, it shifted to a managed-account and syndicated co-investment model, with the European Investment Bank facility announced in December 2023 representing a new dedicated vehicle.

The firm targets expansion and growth equity, with selective exposure to late-stage venture, public-to-private transactions, and pre-IPO rounds. It generally avoids seed-stage clinical risk, preferring companies with commercial revenue and proven reimbursement pathways in their target markets.

TVM Capital Healthcare was carved out from the Munich-based TVM Capital Life Science franchise in 2012 as a distinct legal entity and management team. While Helmut Schühsler was involved in both, the Dubai firm operates with a separate investment mandate, limited partner base, and regulatory domicile focused on healthcare delivery and regional expansion rather than early-stage biotech drug development.

The traditional focus has been the Gulf Cooperation Council countries, with a secondary mandate in Southeast Asia. In December 2023, a new European Investment Bank-backed facility expanded the firm's geographic scope to include the Southern Mediterranean and Sub-Saharan Africa, marking a deliberate pivot to broader emerging-market healthcare investing.